Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

2026-01-27 - 11:36

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer’s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million SHANGHAI, Jan.